Lindsay Speer
Family · Sioux Falls, SDNPI 1447584743
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,005, 4.5 times the $222 reported in 2021. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$539
- Novo Nordisk$501
- Pfizer$411
- Lilly USA, LLC$319
- Amgen$197
- Mylan Specialty L.p.$129
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,241100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $539 |
| Novo Nordisk | 37 | $501 |
| Pfizer | 30 | $411 |
| Lilly USA, LLC | 20 | $319 |
| Amgen | 13 | $197 |
| Mylan Specialty L.p. | 8 | $129 |
| Johnson & Johnson | 7 | $101 |
| AstraZeneca | 7 | $99 |
| Astellas Pharma US Inc | 5 | $83 |
| GSK | 5 | $75 |
| Merck | 5 | $69 |
| Dexcom, Inc. | 5 | $62 |
| Boehringer Ingelheim | 4 | $54 |
| Viatris Specialty LLC | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Daiichi Sankyo Inc. | 3 | $45 |
| Bayer | 2 | $41 |
| Grifols USA, LLC | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Radius Health, Inc. | 1 | $31 |
| Boston Scientific | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Novartis | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Insmed, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Medtronic | 1 | $16 |
| Abbott | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$3,241 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 13 | $13,977 |
| OraceaDoxycycline Monohydrate | 11 | $9,349 |
| Rosuvastatin Calcium | 97 | $1,031 |
| SynthroidLevothyroxine Sodium | 16 | $636 |
| Omeprazole | 43 | $450 |
| Levothyroxine Sodium | 58 | $422 |
| Guanfacine Hcl ErGuanfacine Hcl | 24 | $406 |
| Potassium Chloride | 12 | $364 |
| Metformin Hcl ErMetformin Hcl | 33 | $338 |
| Gabapentin | 12 | $332 |
| Losartan Potassium | 35 | $327 |
| Metoprolol Succinate | 17 | $310 |
| Fluticasone Propionate | 18 | $263 |
| Glipizide ErGlipizide | 13 | $247 |
| Escitalopram Oxalate | 12 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $319 | $13,97713 claims |
| AbbVieSynthroid | $539 | $63616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.
Other family in Sioux Falls
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Michelle VanhoveSioux Falls$7K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Megan MoedingSioux Falls$5K
- Kari WestenkirchnerSioux Falls$4K
- Brooke MunkSioux Falls$4K
- Rebekka KlemmeSioux Falls$4K
- Jordyn HoferSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.